{"entity":{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","aka":[],"tldr":"A phase 2 trial of Roginolisib in uveal melanoma, run by iOnctura, active and no longer recruiting.","summary":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma is a phase 2 interventional study registered as NCT06717126 by iOnctura, with 85 participants enrolled, started 2025-02-27 and due to reach its primary completion in 2027-12. Interventions recorded: roginolisib and Investigator choice of standard therapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06717126","url":"https://clinicaltrials.gov/study/NCT06717126"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["roginolisib"],"companies":["ionctura"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06717126","phase":"2","setting":"A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma","sponsor":"iOnctura","enrolled":85,"outcomes":[]},"route":"/trials/nct06717126/","neighbours":{"cancer":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/"}],"company":[{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/"}]}}